Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma

World Journal of Urology

Volumn 29, Issue 3, 2011, Pages 361-366

  Herrmann, E ^a   Marschner, N ^b   Grimm, M O ^c   Ohlmann, C H ^d   Hutzschenreuter, U ^e   Overkamp, F ^f   Groschek, M ^g   Blumenstengel, K ^h   Puhse G ^a   Steiner, T ⁱ  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b Practice for Oncology and Hematology   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

^e Medical Practice for Oncology and Hematology   (Germany)

^f Day Clinic for Hematology and Oncology   (Germany)

^g Medical Practice for Oncology and Hematology   (Germany)

^h NONE   (Germany)

ⁱ JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Renal cell carcinoma; Sequential therapies; Sorafenib; Sunitinib

Indexed keywords

ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; INDOLE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE; SORAFENIB; SUNITINIB;

ARTICLE; CANCER STAGING; CLINICAL TRIAL; DISEASE COURSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG COMBINATION; FEMALE; HUMAN; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; KIDNEY TUMOR; LONGITUDINAL STUDY; MALE; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROTEIN-TYROSINE KINASES; PYRIDINES; PYRROLES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79957504870     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-011-0673-4     Document Type: Article

References (11)

1. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27: 3312-3318.
2. Motzer RJ, Hutson E, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for Sunitinib compared with interferon alpha in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590.
3. Tamaskar A, Garcia JA, Elson P, Wood L, Mekhail T, Dreicer R, Rini BI, Bukowski RM (2008) Antitumour effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 179: 81-86.
4. Eichelberg C, Heuer R, Chun FK, Hinrichs K, Zacharias M, Huland H, Heinzer H (2008) Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 54: 1373-1378.
5. Dudek AZ, Zolnieriek J, Dham A, Lindgren BR, Szczylik C (2009) Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 115: 61-67.
6. Sablin MP, Negrier S, Ravaud A, Oudard S, Balleyguier C, Gautier J, Celier C, Medioni J, Escudier B (2009) Sequentiel sorafenib and sunitinib for renal cell carcinoma. J Urol 182: 29-34.
7. Porta C, Procopio G, Sabbatini R (2010) Retrospective analysis of the sequential use of sorafenib and sunitinib in patients with advanced renal cell carcinoma (RCC). Onkologie 33(Suppl 2): abstr. PO119.
8. Larkin J, Gore M (2010) Is advanced renal cell carcinoma becoming a chronic disease? Lancet 376: 574-575.
9. Stadler WM, Figlin RA, McDermott FD, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM, ARCCS Study Investigators (2010) Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 116: 1272-1280.
10. Beck J, Procopio I, Negrier S (2009) Final analysis of a large open-label, noncomparative, phase 3 study of sorafenib in European patients with advanced RCC (EU-ARCCS). Eur J Cancer Suppl 7: 434.
11. Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Nieto A, Yuan J, Bukowski R (2009) Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10: 757-763.